

Non Union FDA Submittal

Any day now we are expecting to hear the good news that our Pre Market Approval Application for non healing fractures has been delivered to the FDA. M Squared, founded by former HealthTronics Vice President for Regulatory Affairs, Marie Marlow, has been engaged to submit the application. The application will be made by TRT spin-off CRT and TRT will be the exclusive distributor.

Dr. Phil Lavin, renowned Harvard Biostatistician was also engaged to review the data and to calculate the statistical models that will be submitted to the FDA. The data was compiled by the Trauma Center, Meidlin, Vienna, Austria in their daily treatments for non healing fractures in Austria as part of the workman's compensation medical system. Shockwaves are the standard of care for the treatment of non healing fractures in Austria and it has replaced the current standard of care in American, bone growth stimulators (Exogen). Our data shows that we have an 80% success rate when treating non unions averaging 20 months in age that have failed two previous surgical interventions. This is a single non invasive treatment lasting about 30 minutes that has been proven to reduce the associated healthcare costs by 90%. When extended to the American system where non unions cost over \$125,000 per patient to manage, this represents annual savings of hundreds of millions of dollars.

**IN FUTURE, TRT NEWSLETTERS
WILL BE AVAILABLE ONLY BY
EMAIL OR ON THE TRT WEB SITE.**

American Urological

TRT will attend and exhibit at the AUA in San Diego, CA, May 4 – 8. Mark Gronowski, John and Robert Warlick, and the rest of the sales team will be in attendance and we look forward to meeting with our shareholders and partners. We will be scheduling an informal gathering at a local watering hole to spend some quality time with our investors and answer any questions. Please stop by the booth to get an invitation and let us know if you will be able to attend. There will be several papers presented at the AUA showing the benefits of Shockwaves in novel urological applications such as incontinence and erectile dysfunction. Please plan on attending Dr. Tom Lue's (UCSF) residents presentation on the female stress incontinence model and the positive effects of shockwaves. This paper won the prestigious Lapides Essay Award (2nd place) and it will be presented at the AUA.

ISMST

Please be reminded that the 16th annual meeting of the ISMST will be held in Salzburg Austria June 27 -29. I strongly encourage our investors to attend this meeting and enjoy beautiful Austria. This meeting totally reinvigorates our staff by reminding us that shockwaves will one day become the low cost, pain free standard of care for managing indications across a broad spectrum of applications, from urology to cardiovascular disease.

Website

For further details, submission of abstracts and registration please visit our website:
www.ismst.com
www.shockwavetherapy.org

Congress Language

The congress language is English.

Industrial Exhibition

An industrial exhibition will present the latest progress in equipment for ESWT.

Social Programme

A number of social events will be a pleasant opportunity to discover Salzburg's numerous attractions and for informal discussions.

Information about Salzburg

www.salzburg.info/en

pictures © Tourismus Salzburg



Congress Secretariat

Austrian Workers' Compensation Board (AUVA),
 Office for International Relations and Conferences,
 Adalbert-Stifter-Straße 65, 1200 Vienna, Austria
 Phone: +43 1 331 11-261, Fax +43 1 331 11-469
 E-mail: ISMST2013@auva.at

CWI

Training and device delivery has been completed at all four CWI sites (Mississippi, Alabama, Missouri, and Israel) and patient recruitment is only awaiting final IRB approval. This should be any day now. Also, the annual investigators' meeting was held in Washington, D.C on February 28.

The CWI program has recently reached out to the NFL to offer collaboration on studies that would benefit football players as well as combat veterans. Specifically, CWI research supports that shockwaves may be beneficial in managing head trauma associated with repetitive high speed impacts and other sports injuries. The NFL recently funded a 10 year \$100,000,000 research fund that will be managed by Harvard. We have offered our services to Harvard and the NFL.

Osteoporosis

Our research partners in Rotterdam have just gained approval to begin human clinical trials for osteoporosis. This approval was based on their previous successes in animal models that showed very strong statistical significance in managing this devastating disease. We will deliver a DermaGold 180 device to them in the next month and we eagerly await hearing the preliminary results. We hope to have some news at the next ISMST.

UCSF Research

Dr. Tom Lue, prestigious urological researcher with over 400 publications, recently submitted an application for approval to initiate human clinical trials for female incontinence. Dr. Lue also has groundbreaking research in the mechanism of action for shockwaves and the unique biologic response that includes stem cell recruitment.

Tissue Regeneration Technologies, LLC
130 Arnold Mill Park, Woodstock, GA 30188
Tel: (770) 966-1315 ▪ Tdd: (877) 966-1315
Fax: (770) 592-8910 ▪ Web: www.trtllc.com

New Publication

The article "Shock wave treatment induces angiogenesis and mobilizes endogenous endothelial cells..." has been accepted for publication in the 2nd highest rated cardiothoracic surgical journal, JTCVS. The authors include TRT collaborators Drs. Can Tepekoylu, Johannes Holfeld, Michael Grimm, Feng Shen Wang, and Wolfgang Schaden, et al. This is a ground breaking paper in that it is the first to show progenitor cell mobilization after SW Therapy. Several other associated papers have also been submitted to Journals and we hope to hear more good news soon.

Puerto Rico LithoGold

We recently delivered our first LithoGold outside of the continental United States to Puerto Rico. We also are confident that we will place a second device in the Dominican Republic.

...Of Interest



ED treatment of a rat in San Francisco

This newsletter is not an offer to sell or solicitation of an offer to buy TRT securities. Investment decisions should be based on the risks and disclosures presented in TRT's Confidential Memorandum. This newsletter contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are only predictions and not guarantees of performance. You should not place undue reliance on any forward-looking statements.